Business Context and Reporting Period
This Form 6-K filing by SciSparc Ltd. covers the month of February 2024, with the report dated February 12, 2024. The filing discloses a significant legal development regarding the termination of a key technology license agreement.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a material event rather than periodic financial results.
Material Changes
- License Termination: On February 5, 2024, the Company received written notice from Dekel Pharmaceuticals Ltd. ("Dekel") terminating their License Agreement dated May 20, 2015 (as amended).
- Reason for Termination: Dekel alleges the Company breached material contractual obligations by failing to provide required reports regarding licensed products.
- Effective Date: The termination is effective immediately.
- Scope: The agreement granted the Company an irrevocable, worldwide, exclusive, royalty-bearing license to certain of Dekel's technology.
Management Commentary, Risks, and Contingencies
- Company Position: SciSparc Ltd. disagrees with and rejects Dekel's allegations of breach.
- Intended Action: The Company intends to defend itself vigorously if necessary.
- Business Impact: Management is currently assessing the potential effects of this termination on the Company's business operations.
- Risk: The loss of the exclusive license to Dekel's technology represents a material contingency that could impact future operations, though the outcome of the dispute remains uncertain.
Key Facts for Investor Verification
- Verify the specific terms of the License Agreement (filed as Exhibits 4.4, 4.7, and 4.8 to the 2022 Form 20-F) to understand the reporting obligations and termination clauses.
- Monitor for further legal filings or press releases regarding the dispute between SciSparc and Dekel.
- Assess the dependency of SciSparc's current product pipeline on the licensed technology from Dekel.
- Review the Company's next financial report for any quantified impact on revenue or expenses resulting from this event.